BIOFILCHEM36.00

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹58.6 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)177.02229.48197.73197.73
Receivable Days (DSO)301.12418.68354.60354.60
Payable Days (DPO)1,913.032,128.20843.41396.79
Cash Conversion Cycle (days)-1,434.89-1,480.04-291.08155.54
Working Capital Turnover4.053.121.872.26
Asset Turnover0.850.660.660.66
Cash Conversion (CFO/Net Income)3.37-3.45-0.22-0.22
CFO/EBITDA2.93-2.27-0.93-0.93
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.